STATEMENT UNDER 37 CFR 3.73(b)		
Applicant/Patent Owner: Rasappa G. Arumugham, et al.		
Application No./Patent No.: 10/583,503 File	d/Issue Date: November 17, 2006	
Titled: A-BETA IMMUNOGENIC PEPTIDE CARRIER CONJUC	SATES AND METHODS OF PRODUCING SAME	
Janssen Alzheimer Immunotherapy; Corpo Wyeth LLC , a Limite	d Liability Company	
(Name of Assignees) (Type of A	ussignee: corporation, partnership, university, government agency, etc.)	
states that they are:		
1. the assignee of the entire right, title, and interest in;		
2. an assignee of less than the entire right, title, and interest in (The extent (by percentage) of its ownership interest is%); or		
 Janssen Alzheimer Immunotherapy and Wyeth LLC are each an assignee of an undivided right, title, and interest in the patent application identified above. There are no other assignees. 		
the patent application/patent identified above, by virtue of either:		
A. An assignment from the inventor(s) of the patent applicatio in the United States Patent and Trademark Office at Reel _ copy thereof is attached.	n/patent identified above. The assignment was recorded , Frame, or for which a	
OR	en e	
B. A chain of title from the inventor(s), of the patent application/patent identified above, to the current assignee as follows:		
From: Rasappa G. Arumugham and A. Krishna To: Prasad	Wyeth and Elan Pharmaceuticals, Inc.	
The document was recorded in the United States Pate	ent and Trademark Office at	
Reel 019315 , Frame 0037	, or for which a copy thereof is attached.	
2. From: Elan Pharmaceuticals, Inc. To:	Neuralab Limited	
The document was recorded in the United States Pate	ent and Trademark Office at	
Reel 022698 , Frame 0698	, or for which a copy thereof is attached.	
3. From: Neuralab Limited To:	Elan Pharma International Limited	
The document was recorded in the United States Pat-	ent and Trademark Office at	
Reel 022701 , Frame 0714	_ , or for which a copy thereof is attached.	
Additional documents in the chain of title are listed on a	supplemental sheet (s).	
As required by 37 CFR 3.73(b)(1)(i), the documentary evidence was, or concurrently is being, submitted for recordation pursuant		
[NOTE: A separate copy (i.e., a true copy of the original assignment document(s)) must be submitted to Assignment Division in accordance with 37 CFR Part 3, to record the assignment in the records of the USPTO. See MPEP 302.08]		
The undersigned (whose title is supplied below, is authorized to act assignee.	on behalf of Janssen Alzheimer Immunotherapy, an	
Signature		
Rosemarie L. Celli, Registration No. 42,397 Attorney of Record		
Typed or Printed Name	Title	

Supplemental Sheet to Statement Under 3.73(b) Attorney Docket No.: 057436-392012

Application No.: 10/583,503

Filing Date: November 17, 2006

Additional documents in the chain of title:

4.	From:	Elan Pharma International Limited To: Crimagua Limited and Wyeth
		The document was recorded in the United States Patent and Trademark Office a
		Reel: 023435 Frame: 0029; or for which a copy thereof is attached.
5.	From:	Crimagua Limited To: Janssen Alzheimer Immunotherapy and Wyeth
		The document was recorded in the United States Patent and Trademark Office a
		Reel: 023435 Frame: 0045; or for which a copy thereof is attached.
6.	From:	Change of Name Wyeth To: Wyeth LLC
		The document was recorded in the United States Patent and Trademark Office a
		Reel: 024160 Frame: 0365 : or for which a copy thereof is attached.